Dianthus (DNTH) Therapeutics announced completion of enrollment in the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis. DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein. Initial top-line results from the MaGic trial are anticipated in September 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Short Report: Bears bite into solar with higher exposure to Sunrun, SolarEdge
- Short Report: Bears focus on crypto space, boost bets on CleanSpark, Mara
- Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress
- Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating
- Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress